Literature DB >> 21512415

Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?

Adi F Gazdar1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512415      PMCID: PMC4513359          DOI: 10.1097/MD.0b013e31821a2f07

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


× No keyword cloud information.
  2 in total

1.  Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients.

Authors:  Lauren L Palazzo; Deirdre F Sheehan; Angela C Tramontano; Chung Yin Kong
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-02-20       Impact factor: 4.254

2.  Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Authors:  Yu-Mu Chen; Chien-Hao Lai; Huang-Chih Chang; Tung-Ying Chao; Chia-Cheng Tseng; Wen-Feng Fang; Chin-Chou Wang; Yu-Hsiu Chung; Kuo-Tung Huang; Hung-Cheng Chen; Ya-Chun Chang; Meng-Chih Lin
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.